BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 27479930)

  • 1. Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis.
    Azoulay L; Filion KB; Platt RW; Dahl M; Dormuth CR; Clemens KK; Durand M; Hu N; Juurlink DN; Paterson JM; Targownik LE; Turin TC; Ernst P; ; Suissa S; Dormuth CR; Hemmelgarn BR; Teare GF; Caetano P; Chateau D; Henry DA; Paterson JM; LeLorier J; Levy AR; Ernst P; Platt RW; Sketris IS
    JAMA Intern Med; 2016 Oct; 176(10):1464-1473. PubMed ID: 27479930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study.
    Azoulay L; Filion KB; Platt RW; Dahl M; Dormuth CR; Clemens KK; Durand M; Juurlink DN; Targownik LE; Turin TC; Paterson JM; Ernst P;
    BMJ; 2016 Feb; 352():i581. PubMed ID: 26888382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus.
    Faillie JL; Yu OH; Yin H; Hillaire-Buys D; Barkun A; Azoulay L
    JAMA Intern Med; 2016 Oct; 176(10):1474-1481. PubMed ID: 27478902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.
    Li L; Shen J; Bala MM; Busse JW; Ebrahim S; Vandvik PO; Rios LP; Malaga G; Wong E; Sohani Z; Guyatt GH; Sun X
    BMJ; 2014 Apr; 348():g2366. PubMed ID: 24736555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study.
    Knapen LM; de Jong RG; Driessen JH; Keulemans YC; van Erp NP; De Bruin ML; Leufkens HG; Croes S; de Vries F
    Diabetes Obes Metab; 2017 Mar; 19(3):401-411. PubMed ID: 27883260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study.
    Thomsen RW; Pedersen L; Møller N; Kahlert J; Beck-Nielsen H; Sørensen HT
    Diabetes Care; 2015 Jun; 38(6):1089-98. PubMed ID: 25633664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
    Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
    Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study.
    Faillie JL; Azoulay L; Patenaude V; Hillaire-Buys D; Suissa S
    BMJ; 2014 Apr; 348():g2780. PubMed ID: 24764569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Multicenter Observational Study of Incretin-based Drugs and Heart Failure.
    Filion KB; Azoulay L; Platt RW; Dahl M; Dormuth CR; Clemens KK; Hu N; Paterson JM; Targownik L; Turin TC; Udell JA; Ernst P;
    N Engl J Med; 2016 Mar; 374(12):1145-54. PubMed ID: 27007958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study.
    Abrahami D; Douros A; Yin H; Yu OH; Faillie JL; Montastruc F; Platt RW; Bouganim N; Azoulay L
    BMJ; 2018 Dec; 363():k4880. PubMed ID: 30518618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incretin-based drugs and the risk of congestive heart failure.
    Yu OH; Filion KB; Azoulay L; Patenaude V; Majdan A; Suissa S
    Diabetes Care; 2015 Feb; 38(2):277-84. PubMed ID: 25205143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials.
    Abd El Aziz M; Cahyadi O; Meier JJ; Schmidt WE; Nauck MA
    Diabetes Obes Metab; 2020 Apr; 22(4):699-704. PubMed ID: 31750601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes.
    Abrahami D; Yin H; Yu OHY; Pollak MN; Azoulay L
    Epidemiology; 2018 Mar; 29(2):246-253. PubMed ID: 29283894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study.
    Chou HC; Chen WW; Hsiao FY
    Drug Saf; 2014 Jul; 37(7):521-8. PubMed ID: 24859164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incretin-Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes.
    Faillie JL; Yin H; Yu OHY; Herrero A; Altwegg R; Renoux C; Azoulay L
    Clin Pharmacol Ther; 2022 Jan; 111(1):272-282. PubMed ID: 34587280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of incretin agents and risk of pancreatic cancer: a population-based cohort study.
    Knapen LM; van Dalem J; Keulemans YC; van Erp NP; Bazelier MT; De Bruin ML; Leufkens HG; Croes S; Neef C; de Vries F; Driessen JH
    Diabetes Obes Metab; 2016 Mar; 18(3):258-65. PubMed ID: 26537555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?
    Olansky L
    Cleve Clin J Med; 2010 Aug; 77(8):503-5. PubMed ID: 20682512
    [No Abstract]   [Full Text] [Related]  

  • 18. Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes.
    Brauer R; Wei L; Ma T; Athauda D; Girges C; Vijiaratnam N; Auld G; Whittlesea C; Wong I; Foltynie T
    Brain; 2020 Oct; 143(10):3067-3076. PubMed ID: 33011770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: A population-based study in Taiwan.
    Tseng CM; Liao WC; Chang CY; Lee CT; Tseng CH; Hsu YC; Lin JT
    Pancreatology; 2017; 17(1):76-82. PubMed ID: 27743712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink.
    Gamble JM; Chibrikov E; Midodzi WK; Twells LK; Majumdar SR
    BMJ Open; 2018 Oct; 8(10):e023830. PubMed ID: 30297350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.